Top 5 Stocks to Buy Now
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free SMFL Stock Alerts

Smart for Life (SMFL) Competitors

Smart for Life logo
$0.0020 0.00 (0.00%)
As of 06/18/2026 02:20 PM Eastern
Compare

SMFL vs. ADTX, SCPS, ARDS, TRVN, and NAVB

Should you buy Smart for Life stock or one of its competitors? MarketBeat compares Smart for Life with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Smart for Life include Aditxt (ADTX), Scopus BioPharma (SCPS), Aridis Pharmaceuticals (ARDS), Trevena (TRVN), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry.

How does Smart for Life compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Smart for Life
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Aditxt has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Smart for Life has a beta of 14.81, suggesting that its stock price is 1,381% more volatile than the broader market.

15.5% of Aditxt shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 0.0% of Aditxt shares are held by company insiders. Comparatively, 31.7% of Smart for Life shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Smart for Life has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Smart for Life's return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Aditxt-360,152.50% -374.60% -105.93%
Smart for Life N/A N/A N/A

In the previous week, Aditxt had 6 more articles in the media than Smart for Life. MarketBeat recorded 6 mentions for Aditxt and 0 mentions for Smart for Life. Aditxt's average media sentiment score of 0.24 beat Smart for Life's score of 0.00 indicating that Aditxt is being referred to more favorably in the media.

Company Overall Sentiment
Aditxt Neutral
Smart for Life Neutral

Smart for Life has higher revenue and earnings than Aditxt. Smart for Life is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aditxt$14.34K0.59-$41.71M-$100.79 thousandN/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Summary

Smart for Life beats Aditxt on 9 of the 14 factors compared between the two stocks.

How does Smart for Life compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Smart for Life Neutral

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Smart for Life N/A N/A N/A

28.4% of Smart for Life shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 31.7% of Smart for Life shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Scopus BioPharma has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market. Comparatively, Smart for Life has a beta of 14.81, meaning that its share price is 1,381% more volatile than the broader market.

Scopus BioPharma has higher earnings, but lower revenue than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Summary

Smart for Life beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Smart for Life compare to Aridis Pharmaceuticals?

Smart for Life (NASDAQ:SMFL) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Smart for Life has a beta of 14.81, suggesting that its stock price is 1,381% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 44.97, suggesting that its stock price is 4,397% more volatile than the broader market.

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Aridis Pharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

Smart for Life has higher revenue and earnings than Aridis Pharmaceuticals. Smart for Life is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.03

Summary

Smart for Life beats Aridis Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Smart for Life compare to Trevena?

Trevena (NASDAQ:TRVN) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Trevena Neutral
Smart for Life Neutral

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Smart for Life N/A N/A N/A

Trevena has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Smart for Life has a beta of 14.81, meaning that its share price is 1,381% more volatile than the broader market.

13.6% of Trevena shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 31.7% of Smart for Life shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Smart for Life has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Summary

Smart for Life beats Trevena on 8 of the 9 factors compared between the two stocks.

How does Smart for Life compare to Navidea Biopharmaceuticals?

Smart for Life (NASDAQ:SMFL) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Smart for Life has a beta of 14.81, meaning that its share price is 1,381% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

28.4% of Smart for Life shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 31.7% of Smart for Life shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Navidea Biopharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Smart for Life. Smart for Life is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Summary

Smart for Life beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

Get Smart for Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for SMFL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SMFL vs. The Competition

Export
MetricSmart for LifeMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$14K$4.16B$6.42B$12.60B
Dividend YieldN/AN/A2.68%5.68%
P/E Ratio0.009.2024.4924.43
Price / Sales0.001.97528.27108.62
Price / CashN/A7.5345.0755.09
Price / Book0.001.5710.836.58
Net Income-$22.68M$10.91M$3.57B$337.17M
7 Day PerformanceN/A-2.82%0.77%0.82%
1 Month PerformanceN/A-19.09%1.41%3.25%
1 Year PerformanceN/A17.23%29.35%36.02%

Smart for Life Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMFL
Smart for Life
N/A$0.00
flat		N/A-94.4%$14K$11.11MN/A110
ADTX
Aditxt
1.0426 of 5 stars		$0.01
-29.7%		N/A-100.0%$20KN/AN/A60
SCPS
Scopus BioPharma
N/A$0.00
-33.3%		N/AN/A$17KN/AN/A9
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/AN/A$11KN/A0.0030
TRVN
Trevena
N/A$0.01
flat		N/A-99.0%$11K$443KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SMFL) was last updated on 6/20/2026 by MarketBeat.com Staff.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Forget the million-dollar nest egg
Nearly 2 in 3 Americans fear running out of money more than death - and chasing a $1.5 million nest egg isn't ...
Investors Alley | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Read this before you touch SPCX
SPCX is live on Nasdaq - but a market expert who called AMD before it climbed as high as 7,100% says buying th...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
Elon Now Pays 15X More Than Your Bank
Elon Musk's new bank is offering 6% interest per year - that's 15 times the national average of 0.4% that most...
InvestorPlace | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel